{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:15:00Z","timestamp":1793661300326,"version":"4.5.1"},"reference-count":31,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:00:00Z","timestamp":1669593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Infectious Disease Reports"],"abstract":"<jats:p>Standardized treatment regimens for chronic hepatitis B (CHB) are crucial in suppressing viral replication, disease progression and the development of complications. However, information on routine compliance with such therapeutic recommendations in medical practice is rare. Aim: To evaluate the application of Brazilian therapeutic guidelines for CHB within the scope of the Unified Health System in Minas Gerais state. Four key recommendations from the national guidelines were compared with data from treated patients: (i) eligibility to start treatment; (ii) type of treatment applied; (iii) rescue antiviral therapy; and (iv) monitoring of virological response. Most physicians (69.8%) declared to adopt these guidelines, while 10 of them were unaware. However, according to the criteria established by the guidelines, only 39.5% of treated patients should have been considered \u201ctruly\u201d eligible to start treatment and only 67.6% of these underwent the recommended pharmacological treatment. The virological response was laboratory monitored in just over a third of patients. Rescue therapy was adequately supplanted in 41.2% of patients previously treated with lamivudine. There was low compliance with national guidelines by public service physicians in Brazil, highlighting the need to raise awareness of the importance of its adherence to expand the control of CHB. Thus, increasing the adherence of health professionals to this tool is a current challenge for health institutions and managers.<\/jats:p>","DOI":"10.3390\/idr14060094","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T08:43:03Z","timestamp":1669624983000},"page":"955-966","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Noncompliance with Therapeutic Guidelines for Chronic Hepatitis B Patients in Minas Gerais, Brazil"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5542-3137","authenticated-orcid":false,"given":"Cristiane Faria Oliveira","family":"Scarponi","sequence":"first","affiliation":[{"name":"Research and Development Board, Ezequiel Dias Foundation, Belo Horizonte CEP 31510-010, MG, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Ant\u00f4nio Ferreira","family":"Pedrosa","sequence":"additional","affiliation":[{"name":"GeOpem Engenharia e Tecnologia Limitada, Rua Manoel In\u00e1cio Bezerra 192, Brejo Santo CEP 63260-000, CE, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2568-3579","authenticated-orcid":false,"given":"Marcos Paulo Gomes","family":"Mol","sequence":"additional","affiliation":[{"name":"Research and Development Board, Ezequiel Dias Foundation, Belo Horizonte CEP 31510-010, MG, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirceu Bartolomeu","family":"Greco","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Federal University of Minas Gerais, Av. Prof. Alfredo Balena 190, Santa Efig\u00eania, Belo Horizonte CEP 30130-100, MG, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,28]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2017). Global Hepatitis Report 2017, WHO."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1093\/cid\/ciy598","article-title":"Mortality among Patients with Chronic Hepatitis B (CHB) Infection: The Chronic Hepatitis Cohort Study (CHeCS)","volume":"68","author":"Bixler","year":"2019","journal-title":"Clin. Infect Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e8454","DOI":"10.1097\/MD.0000000000008454","article-title":"Effective viral suppression is necessary to reduce hepatocellular carcinoma development in cirrhotic patients with chronic hepatitis B: Results of a 10-year follow up","volume":"96","author":"Zhang","year":"2017","journal-title":"Medicine"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/jvh.12832","article-title":"Temporal trend and risk determinants of hepatocellular carcinoma in chronic hepatitis B patients on entecavir or tenofovir","volume":"25","author":"Hsu","year":"2018","journal-title":"J. Viral Hepat."},{"key":"ref_5","first-page":"22","article-title":"Current and future directions for the management of hepatitis B","volume":"108","author":"Dusheiko","year":"2018","journal-title":"S. Afr. Med. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1053\/j.gastro.2014.03.048","article-title":"Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: A nationwide cohort study","volume":"147","author":"Wu","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12072-008-9080-3","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2008 update","volume":"2","author":"Liaw","year":"2008","journal-title":"Hepatol. Int."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"(2011). European Association for the Study of the Liver. EASL Clinical practice guidelines: Management of chronic hepatitis B virus infection. J. Hepatol., 55, 245\u2013264.","DOI":"10.1016\/j.jhep.2011.02.023"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1590\/0037-8682-0176-2015","article-title":"Distribution of hepatitis B infection in Brazil: The epidemiological situation at the beginning of the 21 st century","volume":"49","author":"Souto","year":"2016","journal-title":"Rev. Soc. Bras. Med. Trop."},{"key":"ref_11","unstructured":"Minist\u00e9rio da Sa\u00fade (MS), Secretaria de Vigil\u00e2ncia em Sa\u00fade, and Departamento de DST, Aids e Hepatites Virais (2002). Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas para Hepatite Viral Cr\u00f4nica B e Coinfec\u00e7\u00f5es; Portaria SAS\/MS N\u00ba 860, de 4 de Novembro de 2002, MS."},{"key":"ref_12","unstructured":"Minist\u00e9rio da Sa\u00fade (MS) (2013). Secretaria de Vigil\u00e2ncia em Sa\u00fade. Departamento de DST, Aids e Hepatites Virais\u2014Boletim Epidemiol\u00f3gico\u2014Hepatites Virais 2012. Ano III, n\u00b0 01, MS."},{"key":"ref_13","first-page":"597","article-title":"Pereira LRL. An\u00e1lise da assist\u00eancia \u00e0 sa\u00fade aos pacientes com hepatites virais B e C no estado do Amap\u00e1","volume":"35","author":"Kubota","year":"2014","journal-title":"Rev. Ci\u00eanc. Farm. B\u00e1sica Apl."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3810\/pgm.2010.09.2213","article-title":"Chronic hepatitis B: Perceptions in Asian American communities and diagnosis and management practices among primary care physicians","volume":"122","author":"Upadhyaya","year":"2010","journal-title":"Postgrad. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1007\/s10620-013-2889-1","article-title":"Chronic hepatitis B management based on standard guidelines in community primary care and specialty clinics","volume":"58","author":"Ku","year":"2013","journal-title":"Dig. Dis. Sci."},{"key":"ref_16","first-page":"624","article-title":"A survey of chronic hepatitis B patient management practices in the European Union","volume":"17","author":"Berg","year":"2010","journal-title":"J. Viral Hepat."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s12072-012-9399-7","article-title":"Are physicians following guidelines? A survey of Hepatitis B management strategies","volume":"7","author":"Lee","year":"2013","journal-title":"Hepatol. Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e02972021","DOI":"10.1590\/0037-8682-0297-2021","article-title":"Low eligibility for hepatitis B treatment in the Brazilian public health system","volume":"55","author":"Scarponi","year":"2022","journal-title":"Rev. Soc. Bras. Med. Trop."},{"key":"ref_19","unstructured":"Minist\u00e9rio da Sa\u00fade (MS), Secretaria de Vigil\u00e2ncia em Sa\u00fade, and Departamento de DST, Aids e Hepatites Virais (2010). Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas para o Tratamento da Hepatite Viral Cr\u00f4nica B e Coinfec\u00e7\u00f5es, S\u00e9rie A. Normas e Manuais T\u00e9cnicos; MS."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies","volume":"12","author":"Altman","year":"2014","journal-title":"Int. J. Surg."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"518","DOI":"10.5152\/tjg.2017.171017","article-title":"Management of special patient groups with hepatitis B virus infection: The EASL 2017 Clinical Practice Guidelines","volume":"28","author":"Idilman","year":"2017","journal-title":"Turk. J. Gastroenterol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1097\/MEG.0b013e32835447fa","article-title":"A survey on the current trends in the management of hepatitis B in China","volume":"24","author":"Ning","year":"2012","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1097\/MEG.0b013e3283154f3a","article-title":"Current trends in chronic hepatitis B management: Results of a questionnaire","volume":"21","author":"Les","year":"2009","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.3111\/13696998.2012.710690","article-title":"Adherence, persistence, healthcare utilization, and cost benefits of guideline-recommended hepatitis B pharmacotherapy","volume":"15","author":"Han","year":"2012","journal-title":"J. Med. Econ."},{"key":"ref_25","first-page":"7-2","article-title":"Analysis of clinical protocol and guidelines therapeutic for treatment for chronic hepatitis B in northeast Brazil and regions north","volume":"14","author":"Pacheco","year":"2016","journal-title":"Rev. Soc. Bras. Clin. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/ajg.2014.72","article-title":"Poor adherence to AASLD guidelines for chronic hepatitis B management and treatment in a large academic medical center","volume":"109","author":"Wu","year":"2014","journal-title":"Am. J. Gastroenterol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s11606-010-1549-9","article-title":"Adherence to chronic hepatitis B treatment guideline recommendations for laboratory monitoring of patients who are not receiving antiviral treatment","volume":"26","author":"Juday","year":"2011","journal-title":"J. Gen. Intern. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1365-2036.2009.03961.x","article-title":"Screening for hepatitis B, C and non-alcoholic fatty liver disease: A survey of community-based physicians","volume":"29","author":"Kallman","year":"2009","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: A 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol. Int."},{"key":"ref_30","unstructured":"World Health Organization (2015). Policy Brief: Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection, WHO."},{"key":"ref_31","unstructured":"Minist\u00e9rio da Sa\u00fade (MS), Secretaria de Vigil\u00e2ncia em Sa\u00fade, and Departamento de Doen\u00e7as de Condi\u00e7\u00f5es Cr\u00f4nicas e Infec\u00e7\u00f5es Sexualmente Transmiss\u00edveis (2022). Boletim Epidemiol\u00f3gico\u2014Hepatites Virais 2022, N\u00famero Especial Jun. 2022; MS."}],"container-title":["Infectious Disease Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2036-7449\/14\/6\/94\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:28:12Z","timestamp":1760146092000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2036-7449\/14\/6\/94"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,28]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["idr14060094"],"URL":"https:\/\/doi.org\/10.3390\/idr14060094","relation":{},"ISSN":["2036-7449"],"issn-type":[{"value":"2036-7449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,28]]}}}